Skip to main content
Loading

Poster Presentation: Solving the Bispecific Antibody Mispairing Challenge in Preclinical R&D

28 Oct 2024
Bi/Multispecifics
Poster Presentation: Solving the Bispecific Antibody Mispairing Challenge in Preclinical R&D
Successful bispecific antibody production requires the correct assembly of multiple peptide chains to achieve a properly heterodimeric molecule. Many mutation sets exist to promote the desired arrangement of heterodimeric heavy chain pairs. However, fewer strategies address the correct pairing of heavy and light chains. The bYlok® bispecific pairing technology developed by Lonza solves heavy and light chain mispairing by engineering precise disulfide bridges within the bispecific molecule. As the sole provider licensed to offer the bYlok® technology for use in R&D at the transient scale, here, evitria AG demonstrates the effectiveness of bYlok® to produce molecules with >95% pure heterodimers with just a single Protein A-based purification.
Industry Experts
Dylan Brethour, Senior Account Manager - Evitria